Hepatitis drugs market
Global Hepatitis Drugs Market, By Drug Class (Interferon Alphas, HIV NRTIs, Nucleotide Polymerase/NS5A Inhibitor Combinations, Hepatitis C Protease/NS5A Inhibitor Combinations, NS5A Inhibitors, Nucleotide Polymerase Inhibitors, Nucleoside Analogue Antivirals, and Thrombopoiesis Stimulating Agents), By Disease Type (Hepatitis B, Hepatitis C, and Others), By Route of Administration (Oral and injection), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019-2027
- Aug 2019
- CMI2977
- 173 Pages
- Excel & Pdf
- Pharmaceutical
Hepatitis Drugs Market – Insights
Hepatitis B is a viral infection that affects the liver and leads to acute and chronic liver disorder. According to World Health Organization (WHO) 2018, it is estimated that about 780,000 people die each year due to complication of hepatitis B, such as liver cirrhosis and liver cancer. Hepatitis B virus (HBV) is highly contagious, and is transmitted through contact with the blood or other body fluids of an infected person.
The global hepatitis drugs market size was valued at US$ 21,148.3 million in 2019, and is expected to witness a CAGR of 3.2% over the forecast period (2019 – 2027).
Global Hepatitis Drugs Market Share (%) Analysis, By Drug Class, 2019
Source: Coherent Market Insights Analysis (2019)
Increasing launches of new drugs and regulatory approvals for hepatitis drugs is expected to drive growth of global hepatitis drug market.
Increasing approvals for hepatitis drugs from regulatory authorities is expected to drive the global hepatitis drugs market growth during the forecast period. For instance, in 2016, the U.S. FDA approved the Elbasvir drug for the treatment of hepatitis C, Elbasvir is a highly potent and selective NS5A inhibitor of the hepatitis C virus NS5A replication complex.
Launch of new drugs for hepatitis treatment is expected to drive growth of the hepatitis drugs market during the forecast period. For instance, in 2018, Natco Pharma has launched a fixed dose combination of Sofosbuvir-Daclatasvir tablets for the treatment of Hepatitis C under the brand name Hepcinat Plus, in India.
Hepatitis Drugs Market Restraints
The high capital requirement for manufacturing hepatitis drugs is expected to hinder growth of the hepatitis drugs market over the forecast period. Hepatitis drugs are costly as the manufacturing process requires expensive raw materials such as active pharmaceutical ingredients (APIs) and drug intermediates. The production, isolation, and usage of raw materials for pharmaceutical and biopharmaceutical drug production, is a complex process and requires a skilled workforce, which adds to the overall cost of the pharmaceuticals.
Hepatitis Drugs Market- Regional Insights
On the basis of region, the global hepatitis drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global hepatitis drugs market over the forecast period, owing to increasing government initiative for the prevention of HBV infection. For instance, in 2017, the U.S. Department of Health And Human Service started the National Viral Hepatitis Action Plan 2017-2020 (Action Plan) to fight against viral hepatitis in the US. The plan outlines strategies to achieve four major goals between 2017 and 2020, such as preventing new viral hepatitis infections, reducing deaths and improving the health of people with viral hepatitis.
Asia Pacific is expected to witness a rapid growth in the global hepatitis drugs market over the forecast period owing to rising demand for generic drugs in this region. For instance in 2015, Gilead licensed its hepatitis C drug Sovaldi to seven generic drug manufacturers companies in India to make and sell a low-cost version of the medicine in 91 emerging economies.
Global Hepatitis Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027
Source: Coherent Market Insights Analysis (2019)
Key players operating in the global hepatitis drugs market include Merck & Co. Inc., Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, GlaxoSmithKline PLC., and Cipla Inc.
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Disease Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Landscape
- Epidemiology Analysis
- Reimbursement Scenario
- PEST Analysis
- Global Hepatitis Drugs Market, By Drug Class, 2019 – 2027 (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Interferon Alphas
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- HIV NRTIs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Nucleotide Polymerase / NS5A Inhibitor Combinations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Hepatitis C Protease / NS5A Inhibitor Combinations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- NS5A Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Nucleotide Polymerase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Nucleoside Analogue Antivirals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Thrombopoiesis Stimulating Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Global Hepatitis Drugs Market, By Disease Type, 2019 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Hepatitis B
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Hepatitis C
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Global Hepatitis Drugs Market, By Route of Administration, 2019 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Global Hepatitis Drugs Market, By Distribution Channel, 2019 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Global Hepatitis Drugs Market, By Region, 2019 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, By Region, 2017 – 2027
- Regional Trends
- North America
- Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
- North Africa
- Central Africa
- South Africa
- Middle East
- Market Size and Forecast, By Drug Class, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Disease Type, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2019 – 2027, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2019 – 2027, (US$ Million)l
- Market Size and Forecast, By Country, 2019 – 2027, (US$ Million)
- GCC Countries
- Israel
- Rest of Middle East
- Competitive Landscape
- Company Profiles
- Merck & Co. Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Gilead Sciences Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Bristol Myers Squibb Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- LAURUS Labs
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Zydus Cadila
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Hetero Healthcare Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GlaxoSmithKline PLC.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Cipla Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Analyst Views
- Section
- References
- Research Methodology
- About Us and Sales Contact
*Browse 35 market data tables and 27 figures on "Global Hepatitis Drugs Market” - Global forecast to 2026”